SynthesisCardiovascular & hematological agents in medicinal chemistry2019
Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences.
Synthesis in Cardiovascular & hematological agents in medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Perfluorocarbon-based artificial oxygen carriers in perioperative and surgical care: a scoping review of basic and translational studies.Frontiers in medicine · 2026Pooled it
- Enhancing red blood cell compatibility: in vitro hemagglutination prevention using a trispecific triabody as a blocking fragment for blood group antigens.Journal of biological engineering · 2026Article
- Cocktail-style multifunctional resuscitation fluids: Where are we now in 2026?Journal of anesthesia and translational medicine · 2026Review
- The evolution of artificial red blood cells and recent advances in state-of-the-art oxygen carrier technologies: a narrative review.Blood science (Baltimore, Md.) · 2025Review
- Artificial blood-hope and the challenges to combat tumor hypoxia for anti-cancer therapy.Medical & biological engineering & computing · 2025Review
- Progress in Development of Functional Biological and Synthetic Blood Products to Augment Transfusable Blood Supply in Operational Medicine.Bioengineering (Basel, Switzerland) · 2025Review
- Therapeutic delivery of oxygen using artificial oxygen carriers demonstrates the possibility of treating a wide range of diseases.Journal of nanobiotechnology · 2025Review
- Artificial blood for therapeutic and laboratory usage: Where do we stand?Biomicrofluidics · 2024Review
- Nanorobotic artificial blood components and its therapeutic applications: A minireview.Irish journal of medical science · 2024Review
- Perfluorocarbon-based oxygen carriers: What is new in 2024?Journal of anesthesia and translational medicine · 2024Review
- Development and evaluation of culture media based on extracts of the cyanobacteriumFrontiers in microbiology · 2022Article
- A Novel Cross-Linked Hemoglobin-Based Oxygen Carrier, YQ23, Extended the Golden Hour for Uncontrolled Hemorrhagic Shock in Rats and Miniature Pigs.Frontiers in pharmacology · 2021Article
- Heparin Administered toBiomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial blood is an innovative concept of transfusion medicine where specifically designed compounds perform the task of transport and delivery of oxygen in the body to replace this function of allogenic human blood transfusion. Several molecules have been developed in the past few decades to achieve this objective and continous refinements are being continuously made in the quest of the ideal blood substitute. Currently, available technology manufactures artificial blood from haemoglobin obtained from outdated human/bovine blood (Haemoglobin Based Oxygen Carriers) or utilizing Perfluorocarbons. These synthetic blood substitutes are advantageous in that they do not require compatibility testing, are free from blood borne infections, have prolonged shelf life and do not require refrigeration. Artificial blood is projected to have a significant impact on the development of medical care in the future. It can complement the current blood products for transfusion and create a stable supply of safe and effective products. It is likely to reduce the requirements of blood transfusions drastically especially in settings of trauma and surgery thereby reducing the reliance on banked donated blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.